ZA200804907B - Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists - Google Patents
Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonistsInfo
- Publication number
- ZA200804907B ZA200804907B ZA200804907A ZA200804907A ZA200804907B ZA 200804907 B ZA200804907 B ZA 200804907B ZA 200804907 A ZA200804907 A ZA 200804907A ZA 200804907 A ZA200804907 A ZA 200804907A ZA 200804907 B ZA200804907 B ZA 200804907B
- Authority
- ZA
- South Africa
- Prior art keywords
- angiotensin
- cosmetic
- pharmaceutical compositions
- receptor antagonists
- ace inhibitors
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title 1
- 239000002537 cosmetic Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200401247 | 2004-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200804907B true ZA200804907B (en) | 2009-04-29 |
Family
ID=40935373
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200702216A ZA200702216B (en) | 2004-08-18 | 2005-08-18 | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists |
ZA200804907A ZA200804907B (en) | 2004-08-18 | 2005-08-18 | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200702216A ZA200702216B (en) | 2004-08-18 | 2005-08-18 | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists |
Country Status (6)
Country | Link |
---|---|
US (2) | US20090137556A1 (xx) |
EP (2) | EP2377532A1 (xx) |
AU (1) | AU2005274574B2 (xx) |
CA (1) | CA2578529A1 (xx) |
WO (1) | WO2006018024A2 (xx) |
ZA (2) | ZA200702216B (xx) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102258503B (zh) | 2004-01-22 | 2019-08-16 | 迈阿密大学 | 局部辅酶q10制剂及其使用方法 |
WO2008132756A1 (en) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
EP1992367B1 (en) * | 2007-05-15 | 2012-06-27 | The Procter & Gamble Company | Absorbent article comprising a lotion composition for reducing adherence of feces or menses to the skin |
US20080287896A1 (en) * | 2007-05-15 | 2008-11-20 | The Procter & Gamble Company | Absorbent Article With Hydrophilic Lotion And High Barrier Cuffs |
EP1992366B1 (en) * | 2007-05-15 | 2011-07-06 | The Procter & Gamble Company | Use of a lotion composition on an absorbent article for reducing adherence of feces or menses to the skin |
EP2271325A4 (en) | 2008-04-11 | 2011-11-09 | Cytotech Labs Llc | METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS |
PH12019500030A1 (en) * | 2009-03-09 | 2020-02-10 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
WO2010132486A2 (en) | 2009-05-11 | 2010-11-18 | Cytotech Labs, Llc | Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
US20110300124A1 (en) * | 2009-08-25 | 2011-12-08 | Thornton Joseph P | Soaking agent for the treatment of hemorrhoids and method of use |
US20110236368A1 (en) * | 2009-08-25 | 2011-09-29 | Thornton Joseph P | Oral medication for the treatment of hemorrhoids and method of use |
ES2758349T3 (es) * | 2010-07-15 | 2020-05-05 | Progressare Medinvest B V | Composición para el tratamiento de lesiones de la piel y/o de las uñas |
GR1007516B (el) * | 2010-07-30 | 2012-01-24 | Χρηστος Νικολαου Γκιλιτσης | Φαρμακο για την θεραπεια της νοσου της ψωριασης |
KR101933732B1 (ko) | 2011-04-04 | 2018-12-28 | 버그 엘엘씨 | 중추 신경 시스템 종양들의 치료 방법 |
EP2704706A1 (en) * | 2011-05-06 | 2014-03-12 | Artskin D.O.O. | Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties |
BR102012003136B1 (pt) * | 2012-02-10 | 2018-01-02 | Oxiteno S.A. Indústria E Comércio | Composição hidratante, uso de uma composição hidratante, e, formulação cosmética contendo composição hidratante |
AU2013235266B2 (en) | 2012-03-20 | 2017-10-19 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
US8603549B1 (en) * | 2012-05-25 | 2013-12-10 | Svetlana Baker | Systems and methods for inhibiting formation of stretch marks |
WO2014168993A1 (en) | 2013-04-08 | 2014-10-16 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
CN103479627A (zh) * | 2013-05-16 | 2014-01-01 | 武汉光谷百桥国际生物科技有限公司 | 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用 |
ES2825083T3 (es) | 2013-09-04 | 2021-05-14 | Berg Llc | Métodos de tratamiento contra el cáncer mediante infusión continua de coenzima Q10 |
US9511034B1 (en) | 2013-12-09 | 2016-12-06 | Bio-Silicote, Inc. | Method for applying a skin treatment |
KR20170134636A (ko) | 2015-04-06 | 2017-12-06 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 포유류 대상체에서 피부 색소침착을 감소시키거나, 예방하거나, 그의 축적을 역전시키기 위한 조성물 및 방법 |
KR20200097297A (ko) * | 2017-12-07 | 2020-08-18 | 더마반트 사이언시즈 게엠베하 | Pde-4 억제제의 국소 연고 제형 및 피부 병태 치료에서의 이의 용도 |
KR20220118210A (ko) * | 2021-02-18 | 2022-08-25 | (주)아모레퍼시픽 | 트랜스퍼좀을 포함하는 난용성 효능물질 전달체 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT206114B (de) | 1955-03-23 | 1959-11-10 | Friedl Schreyer | Mittel zum Spannen der Gesichtshaut und Verfahren zu seiner Herstellung |
JPS57166514U (xx) | 1981-04-16 | 1982-10-20 | ||
FR2512651B1 (fr) | 1981-06-24 | 1986-01-17 | Pere Lahaille Jeanne | Produits anti-rides |
US4877805A (en) | 1985-07-26 | 1989-10-31 | Kligman Albert M | Methods for treatment of sundamaged human skin with retinoids |
FR2538247B1 (fr) | 1982-12-23 | 1986-05-23 | Pere Lahaille Jeanne | Pastille anti-rides et/ou traitant la peau |
US4623539A (en) | 1983-02-04 | 1986-11-18 | Tunc Deger C | Nutrient barrier polysaccharide compositions and method of use |
LU85544A1 (fr) | 1984-09-19 | 1986-04-03 | Cird | Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique |
LU85849A1 (fr) | 1985-04-11 | 1986-11-05 | Cird | Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques |
US5160731A (en) | 1986-06-27 | 1992-11-03 | The Procter & Gamble Company | Sunscreen agents, sunscreen compositions and methods for preventing sunburn |
FR2620914B1 (fr) | 1987-09-25 | 1991-11-08 | Oreal | Materiau en feuille pour realiser un traitement cutane ou capillaire, son procede de fabrication et articles realises en ce materiau |
LU87109A1 (fr) | 1988-01-20 | 1989-08-30 | Cird | Esters et thioesters aromatiques,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
JPH03119163A (ja) | 1989-06-05 | 1991-05-21 | Sequa Chemicals Inc | 不織繊維用バインダー |
ZA906583B (en) * | 1989-08-21 | 1991-09-25 | Beth Israel Hospital | Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine |
US5087445A (en) | 1989-09-08 | 1992-02-11 | Richardson-Vicks, Inc. | Photoprotection compositions having reduced dermal irritation |
US5011681A (en) | 1989-10-11 | 1991-04-30 | Richardson-Vicks, Inc. | Facial cleansing compositions |
DK0474126T3 (xx) * | 1990-09-04 | 1997-04-07 | Fujisawa Pharmaceutical Co | |
US5073372A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
WO1993017682A1 (en) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
GR1002207B (en) | 1992-08-06 | 1996-03-27 | Johnson & Johnson Consumer | Skin care compositions containing imidazoles. |
DE4228455A1 (de) * | 1992-08-26 | 1994-09-15 | Beiersdorf Ag | Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Thiolen und/oder Thiolderivaten |
JPH10500669A (ja) * | 1994-04-12 | 1998-01-20 | アルザ・コーポレーション | サイトカイン阻害薬に関するスクリーニング法 |
DE19604190A1 (de) * | 1996-02-06 | 1997-08-07 | Hoechst Ag | Nagelwachstumsfördernde Zubereitungen |
IL131543A (en) * | 1997-02-25 | 2005-08-31 | Univ Michigan | Cosmetic methods and compositions for preventing and treating chronological aging in human skin |
TWI234467B (en) | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
US5885596A (en) | 1997-07-23 | 1999-03-23 | Bristol-Myers Squibb Company | Methods and compositions for fine lines and/or wrinkles |
WO2000024366A1 (de) * | 1998-10-23 | 2000-05-04 | Aventis Pharma Deutschland Gmbh | Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen |
US20040141925A1 (en) * | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
CN101011390A (zh) * | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
AU756156B2 (en) | 1999-03-23 | 2003-01-02 | University Of Southern California | Methods for limiting scar and adhesion formation |
US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
US20030095959A1 (en) * | 2000-11-21 | 2003-05-22 | Access Business Group International Llc. | Topical skin composition |
US6673802B2 (en) * | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
JP2005503378A (ja) * | 2001-08-06 | 2005-02-03 | ジエノメツド・エル・エル・シー | Aceの過剰に関連する疾患の治療方法及び組成物 |
AU2002337815A1 (en) * | 2001-10-05 | 2003-04-22 | Suwalee Chandrkrachang | Active agents using liposome beads |
FR2836042B1 (fr) * | 2002-02-15 | 2004-04-02 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux |
US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
US7276608B2 (en) * | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
MXPA06002053A (es) * | 2003-08-22 | 2006-08-11 | Schering Ag | Derivados de piperazina que inhiben quimiocina y su uso para tratar miocarditis. |
US7273881B2 (en) * | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
AU2005209045B2 (en) * | 2004-01-30 | 2011-02-24 | Ace Aps | Use of ACE inhibitors and/or angiotensin II receptor antagonists for the improving and/or maintaining the skin tone and for the treatment of skin ageing |
-
2005
- 2005-08-18 ZA ZA200702216A patent/ZA200702216B/xx unknown
- 2005-08-18 EP EP11168684A patent/EP2377532A1/en not_active Withdrawn
- 2005-08-18 WO PCT/DK2005/000530 patent/WO2006018024A2/en active Application Filing
- 2005-08-18 AU AU2005274574A patent/AU2005274574B2/en not_active Ceased
- 2005-08-18 CA CA002578529A patent/CA2578529A1/en not_active Abandoned
- 2005-08-18 EP EP05771000A patent/EP1789031A2/en not_active Withdrawn
- 2005-08-18 US US11/573,781 patent/US20090137556A1/en not_active Abandoned
- 2005-08-18 ZA ZA200804907A patent/ZA200804907B/xx unknown
-
2011
- 2011-11-18 US US13/299,696 patent/US20120219514A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1789031A2 (en) | 2007-05-30 |
ZA200702216B (en) | 2008-11-26 |
WO2006018024A2 (en) | 2006-02-23 |
US20090137556A1 (en) | 2009-05-28 |
US20120219514A1 (en) | 2012-08-30 |
CA2578529A1 (en) | 2006-02-23 |
WO2006018024A3 (en) | 2006-04-06 |
AU2005274574A1 (en) | 2006-02-23 |
EP2377532A1 (en) | 2011-10-19 |
AU2005274574B2 (en) | 2011-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200804907B (en) | Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists | |
HUS1600025I1 (hu) | Egy angiotenzin receptor antagonistát és egy NEP inhibitort tartalmazó gyógyászati kombinációk | |
IL179999A (en) | Preparations containing nebibolol and angiotensin receptor II antagonist and their uses | |
IL183583A0 (en) | Quinazoline derivatives and pharmaceutical compositions containing the same | |
EP1808446A4 (en) | IL-18 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION WITH THE ANTAGONIST | |
ZA200606619B (en) | Indazole derivatives and pharmaceutical compositions containing them | |
HK1124558A1 (en) | Pharmaceutical dosage form containing an active principle combination of nifedipine and/or nisoldipine and of an angiotensin ii antagonist | |
IL182494A0 (en) | Non-peptide bradykinin antagonists and pharmaceutical composition therefrom | |
EP1773369A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PEPTIDE TREATMENT | |
IL178067A0 (en) | Pharmaceutical dosage forms and compositions | |
IL179253A0 (en) | Pyrimidine derivatives and pharmaceutical compositions containing the same | |
IL183986A0 (en) | Pharmaceutical compounds and compositions | |
EP1717246A4 (en) | TNF ANTAGONISTS AND TNF INHIBITORS CONTAINING SAME AS ACTIVE INGREDIENTS | |
ZA200702038B (en) | Pharmaceutical composition drospirenone and ethynyle-stradiol | |
ZA200702938B (en) | Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions | |
AU2003269421A8 (en) | Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use | |
IL157398A0 (en) | Pharmaceutical compositions comprising ccr5 antagonists | |
EP1828227A4 (en) | NEW PEPTIDIC AND PEPTIDOID BRADYKININ B1 RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF | |
IL189827A0 (en) | Pharmaceutical dosage forms and compositions comprising lecoztan | |
IL177751A0 (en) | Pharmaceutical composition of (+)-erythro-mefloquine and its use | |
ZA200704717B (en) | Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor | |
ZA200607803B (en) | Pharmaceutical dosage forms and compositions of 5-HT1A receptor antagonists | |
MXPA02001846A (es) | Combinacion farmaceutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversion de la angiotensina i. |